Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
about
Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategiesIon channels as drug targets in central nervous system disorders50 years of hurdles and hope in anxiolytic drug discoveryValidating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramineMolecular targets for treating cognitive dysfunction in schizophrenia.A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophreniaPharmacological Properties of DOV 315,090, an ocinaplon metabolite.Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?GABA(A) receptor α subunits differentially contribute to diazepam tolerance after chronic treatment.Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: a randomized placebo-controlled study.GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics.Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective.The effects of fall-risk-increasing drugs on postural control: a literature review.A Comparison of the α2/3/5 Selective Positive Allosteric Modulators L-838,417 and TPA023 in Preclinical Models of Inflammatory and Neuropathic Pain.Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers.Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.An Overview of the CNS-Pharmacodynamic Profiles of Nonselective and Selective GABA Agonists.The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress.Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.Pharmacology in translation; the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.GSH-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study.Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia.Pharmacodynamic response profiles of anxiolytic and sedative drugs.The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol.
P2860
Q26827100-40257807-745A-4C80-8F68-A24A25A306DDQ27004533-64FC77DC-B367-4AEB-A952-782B91DACC2EQ28297569-19D638FE-F0A3-45E8-AE8A-09C3E489365DQ30488931-A7992D57-A853-4B0C-B7AC-BAAB8F1CD6DAQ30491310-97B1F424-9701-41D9-9B18-23664C6450BEQ30498769-4307EDCD-2283-46BB-8215-57713EEA57CBQ33343725-AC00470A-E4C5-4B17-8F2F-C9232F893EABQ33574884-53586E4E-3F30-43F9-AC35-5F46E5278A34Q33810376-194F162D-8A3A-42CF-8C56-1C349A930C99Q34389218-71264BBB-A34A-40B6-BD93-CE7666CFCF06Q34647740-43A7EAF6-1AA9-40FA-B0ED-A0D2E67E5813Q34778798-5D4B6D0B-571A-4946-AEC8-AA315BAD8B93Q34996934-AA37AAAC-E317-4A72-B7C7-BB5DA05D4192Q37427922-FF310E60-858B-4E85-84BE-EA74089B35D4Q37639811-827894D4-D313-44BA-8CFB-7940C73CB80AQ37780606-E0C100E2-2EC5-4AAE-B0AB-4FFD2266B7F2Q38134320-0E587CCD-22B4-4B77-80BA-2FD633E6F274Q39456055-603017D0-8CE8-4E4B-AC62-A53C28D5111FQ39784796-2FCA3D0C-B376-4023-9444-F3716EBD4061Q40643023-A2A24308-08EF-4079-88EE-3A19C66E8A30Q40748688-4B8FF571-E882-49C0-9434-FD0BB79B1947Q40894855-14EFD460-19CD-4AEB-B7A4-263406DEFD30Q42283018-B6DC1FAA-551D-441D-A93E-BF1FB9470411Q42567743-2077B563-CCD4-42BE-9928-91BFC86430F8Q43106547-C2EB848E-839C-408F-B377-586B4D71DBA8Q43168345-E5A8E0F6-942E-4083-B02A-72CFA4CC3E19Q46246232-027DE3E4-D899-43F5-9677-771AED7C9C87Q46404900-D2A5E8D6-D266-4F30-AEA7-122A04D7417DQ46533458-B493A30D-FAA4-4746-8733-48D333CE7AFDQ47373267-78BA374E-C05A-4DF3-B1E9-E238B8672171Q47547802-3F95D400-C0B8-430E-A51D-0B6D0BA55F94Q48177435-DD6C98B0-D515-4619-8C70-9842E09F10C4Q48178645-786F6387-D40D-4E52-BA6F-B704272860DBQ50262795-8004B20F-54C2-4CF7-A45F-56093C2B61B3
P2860
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@ast
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@en
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@nl
type
label
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@ast
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@en
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@nl
prefLabel
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@ast
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@en
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers.
@nl
P2093
P356
P1476
Pharmacodynamic and pharmacoki ...... placebo in healthy volunteers
@en
P2093
Agrawal NG
Pearson LK
Rijnbeek B
Simpson RC
P304
P356
10.1177/0269881106072343
P407
P577
2006-11-08T00:00:00Z